

Quantitative Analysis of Orphan Nuclear Receptors in Insulin-Resistant C2C12 Skeletal Muscle Cells

Chew GS^{1*}, Gawned M¹, Molina E¹ and Myers SA^{2**}

¹School of Science and Engineering, Federation University, Australia

²School of Health Sciences, University of Tasmania, Australia

*These authors contributed equally to this work

Abstract

Orphan nuclear receptors (ONR) are members of the nuclear receptor (NR) super family of transcription factors that have been known to play a major role in lipid and glucose metabolism in skeletal muscle. Recently, pharmacological evidence supports the view that stimulation of NR alleviates Type 2 Diabetes (T2D). However the ligands and physiological functions of ONRs still remain unknown. To date, no systematic studies have been carried out to screen for ONRs expressed in insulin resistant skeletal muscle cells. Therefore, in this study, we have established a model for insulin resistance (IR) by treating C2C12 skeletal muscle cells with insulin (10nM) for 48 hours. Western Blot analysis of phosphorylated AKT confirmed IR. By quantitative PCR, we identified that a number of the ONRs respond significantly during the progression of cellular insulin resistance which included Coup-tf1, Coup-tf2, Ppar β , NR4As, Reverba, and Rora, some of which have been associated with fatty acid oxidation regulation and glucose homeostasis and therefore could play a role in the aetiology of this disorder. Highlighted were observed increased mRNA expression levels of other ONRs in insulin resistant C2C12 skeletal muscle cells, indicated that these ONRs could potentially play a pivotal regulatory role of insulin secretion in lipid metabolism. Taken together, this study has successfully contributed to the analysis of ONR in IR, and has filled in an important void in the study and treatment of T2D.

Keywords: Orphan nuclear receptors; Transcription factors; Type 2 Diabetes; Insulin resistance

Introduction

Orphan nuclear receptors (ONRs) are members of the nuclear receptor superfamily of transcriptional factors that are implicated in a number of metabolic processes including lipid and glucose metabolism and energy expenditure [1]. Unlike the steroid hormone receptors and other transcription factors of the nuclear receptor superfamily, the ligands for the ONRs are unknown and suggests that there is a host of other signalling pathways that are regulated by undiscovered ligands [2]. This may have wide-reaching implications in many disease states and processes. In particular, the ONRs play a critical role in glucose and lipid metabolism, and energy expenditure [1,3,4] and thus, are currently under investigation for their role in metabolic disease. Accordingly, several ONRs have been examined for their roles in insulin resistance and type 2 diabetes. For example, the liver X receptor (now an adopted ONR due to the identification of a ligand) global knock-out mouse model shows improved muscle, hepatic and adipose tissue insulin sensitivity [5]. Moreover, the PPARs (another class of adopted ONRs) have received much attention as potential pharmacological targets for combating obesity and diabetes due to their important role in cell metabolism (specifically lipid metabolism) regulation [6] and amelioration of insulin resistance in skeletal muscle and liver [7-9].

Although there have been a number of studies on the role of ONRs in insulin resistant mouse models, there is no information, to our knowledge, on the regulatory response of the ONRs in a progressive insulin-resistance skeletal muscle cell system. Accordingly, in this study we aimed to address the regulation of several ONRs in an insulin-resistant mouse C2C12 skeletal muscle. We identified that a number of the ONRs respond significantly during the progression of cellular insulin resistance and therefore could play a role in the aetiology of this disorder.

Experimental

Cell culture and the creation of an insulin-resistant skeletal muscle cell system

Skeletal muscle C2C12 cells were grown in Dulbecco's minimum essential medium (DMEM) supplemented with 10% (v/v) heat-inactivated foetal bovine serum (HI-FBS) in the presence of 1 mM sodium pyruvate, 0.1 mM non-essential amino acid and 2 mM L-glutamine, 100 U/ml penicillin and 100 μ g/ml streptomycin. The cells were maintained at 37°C in an incubator of 5% (v/v) CO₂ atmosphere. The cell culture medium was replaced every three days.

C2C12 myoblast cells were seeded into 6-well plates and allowed to grow until the cells reached 70% confluence before differentiation into skeletal muscle cells with 2% horse serum for 5 days. Prior to treatment with insulin, the cells were washed twice with PBS and pre-incubated for 4 hr in medium containing 0.5% (v/v) HI-FBS. The medium was then removed and replaced with fresh medium with 0.5% (v/v) HI-FCS in the presence of IL-6 and incubated at 37°C in a humid atmosphere of air containing 5% (v/v) CO₂ for the requisite time. For the development of insulin-resistant skeletal muscle phenotype, C2C12 cells were exposed to chronic insulin (10 nM) treatments over the series of 0 h, 0.5 h, 2 h, 4 h, 8 h, 24 h, and 48 h (12). Media was refreshed every eight

*Corresponding author: Stephen Myers, School of Health Sciences, University of Tasmania, Australia, Tel: +61 3 6324 5459; E-mail: stephen.myers@utas.edu.au

Received October 26, 2015; Accepted November 18, 2015; Published November 24, 2015

Citation: Chew GS, Gawned M, Molina E, Myers SA (2015) Quantitative Analysis of Orphan Nuclear Receptors in Insulin-Resistant C2C12 Skeletal Muscle Cells. J Diabetes Metab 6: 626. doi:10.4172/2155-6156.1000626

Copyright: © 2015 Chew GS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

hours to avoid depleting media components and insulin. For protein phosphorylation detection, 10 nM insulin was added for 30 min before cell lysates harvest at each time point [10]. For control samples, fresh medium with 0.5% (v/v) HI-FCS, without insulin, was used. Following completion of the incubation period, the cells were harvested for RNA isolation and protein extract.

Isolation of total cellular RNA

Total cellular RNA was isolated from cells cultured in 6-well tissue culture plates using TRIzol Reagent (Ambion®) according to the manufacturer's instruction. Briefly, cells were first rinsed twice with PBS and then lysed on the addition of 1ml of Tri-Reagent. The homogenate was then incubated at room temperature for 5 min followed by vortexing in 100 µl of chloroform. The RNA was extracted by centrifugation at 12,000 x g for 15 min at 4°C followed by precipitation with isopropanol. The concentration and purity of the isolated RNA was determined by measuring the absorbance at 260 nm and 280 nm using NANODROP 2000 (Thermo Scientific®).

Synthesis of cDNA and Real-Time PCR

Two µg of total RNA was reverse transcribed into cDNA with the High Transcriptase cDNA kit (Life Technology®). Quantitative Real-Time PCR was carried out using SYBR[®] Green (Bioline®) according to the manufacturer's instructions. The level of gene expression was then measured using Vii7 qPCR machine (Life Technologies®). Specifically, 25 ng of cDNA was added to 5 µl of SYBR[®] Green RT-PCR reaction mix (Bioline®), 10 mM each of the forward primer and reverse primer (Geneworks®) (Table 1), and 0.5 µl of nuclease free water in a

final volume of 10 µl. Quantitative Real-Time PCR was then performed on a ViiA7 qPCR machine (Life Technologies®) using the following method: PCR reaction protocol consisted 40 cycles of denaturation at 95°C for 20 sec; annealing at 60°C for 30 sec, and an extension at 72°C for 30 sec. This was followed by the melt curve analysis which was carried out at 95°C for 1 min, 55°C for 1 min and 40 cycles of 70°C for 10 sec, increasing by 0.5°C each cycle. PCR products were normalized against the housekeeping gene, eukaryotic elongation factor 2 (*Eef2*).

Western blot analysis

Protein extracts used in Western blot analysis were extracted using RIPA buffer® (Ambion®) containing Halt protease and phosphatase inhibitor cocktail (Thermo Fisher Scientific®) according to the manufacturer's instructions. Protein samples (20µg) were used in SDS-PAGE in order to determine the levels of protein content for phosphorylated, Tyr30 AKT and total AKT, respectively. Subsequently, proteins were transferred to a polyvinylidene difluoride membrane (Milipore®) and incubated with blocking solution (1X PBS containing 5% (w/v) skimmed milk powder and 0.1% (v/v) Tween-20) for 1 h at room temperature with shaking. The membrane was washed three times for 10 min each in washing solution (1X PBS and 0.1% (v/v) Tween-20) and incubated with primary antibodies (rabbit anti-mouse Tyr30 AKT, and total AKT), which was diluted 1/1000 in 1X PBS containing 1% (w/v) skimmed milk powder and 0.1% (v/v) Tween-20, for 1 h at room temperature. The membrane was then washed and immersed in secondary antibody (peroxidase-conjugated goat anti-rabbit IgG) diluted 1/2000 in 1X PBS containing 1% (w/v) skimmed milk powder and 0.1% (v/v) Tween-20. Detection of membrane-bound antigen-antibody complexes as immunoreactive signals was detected

	Time (mins)						
	NR 0 0.5 2 4 8 24 48						
	Relative Expression against EEF2 ± SD						
<i>Coupt-1</i>	126.0 ± 5.5	85.8 ± 0.90	99.09 ± 5.90	88.07 ± 2.26	83.44 ± 4.70	20.57 ± 2.90^{***}	89.91 ± 4.27
<i>Coup-tf2</i>	564.12 ± 17.89	409.81 ± 19.57	597.64 ± 8.57	571.62 ± 11.71	434.74 ± 45.03	111.52 ± 3.85^{***}	293.08 ± 16.33
<i>Ppar α</i>	1.28 ± 0.066	1.61 ± 0.203	1.45 ± 0.070	1.30 ± 0.150	1.56 ± 0.110	2.20 ± 0.45	0.855 ± 0.03
<i>Ppar β</i>	635.60 ± 40.23	498.06 ± 40.11	746.39 ± 165.80	683.01 ± 32.40	549.11 ± 12.56	1515.96 ± 38.22^{***}	574.52 ± 28.47
<i>Ppar γ</i>	43.31 ± 3.80	27.10 ± 9.79	44.61 ± 2.78	36.33 ± 0.38	26.04 ± 1.57	34.52 ± 2.29	33.61 ± 2.45
<i>Nor-1</i>	13.98 ± 1.71	18.20 ± 0.83	153.37 ± 7.89^{***}	22.63 ± 1.50	61.82 ± 3.38	487.34 ± 14.40^{***}	74.32 ± 0.95
<i>Nurr1</i>	5.83 ± 0.53	14.15 ± 1.48	67.63 ± 2.60	10.19 ± 2.5	21.0 ± 2.38	108.6 ± 3.11^{**}	8.93 ± 1.24
<i>Nurr77</i>	44.12 ± 0.58	574.41 ± 68.73^{***}	1084.83 ± 53.97^{***}	26.08 ± 0.17	104.26 ± 4.18	504.54 ± 8.01^{***}	44.35 ± 3.0
<i>Reverb α</i>	160.69 ± 10.61	155.23 ± 3.35	151.85 ± 6.21	154.14 ± 1.95	530.33 ± 5.18^{***}	1080.14 ± 48.62^{***}	141.07 ± 6.21
<i>Reverb β</i>	0.25 ± 0.072	0.17 ± 0.04	0.17 ± 0.06	0.20 ± 0.11	0.32 ± 0.15	0.50 ± 0.20	0.35 ± 0.16
<i>Rar α</i>	148.43 ± 18.60	125.63 ± 15.35	104.27 ± 14.48	164.10 ± 16.14	183.88 ± 6.41	203.49 ± 3.80	127.75 ± 9.45
<i>Rar β</i>	4.40 ± 0.18	4.06 ± 0.57	3.96 ± 0.15	3.62 ± 0.53	8.05 ± 0.59	7.15 ± 0.74	8.8 ± 0.82
<i>Rar γ</i>	16.39 ± 2.5	9.35 ± 0.66	12.31 ± 1.74	16.79 ± 3.85	14.13 ± 1.30	6.51 ± 1.02[*]	17.90 ± 0.32
<i>Err α</i>	132.65 ± 5.62	114.19 ± 5.08	111.96 ± 14.25	167.08 ± 1.65	193.07 ± 4.78	395.98 ± 13.96^{***}	163.63 ± 4.25
<i>Err β</i>	0.70 ± 0.35	0.38 ± 0.10	0.77 ± 0.07	0.92 ± 0.01	0.59 ± 0.08	0.76 ± 0.14	0.43 ± 0.05
<i>Lxr α</i>	88.43 ± 130.76	84.88 ± 16.73	168.43 ± 45.73	87.37 ± 20.62	152.99 ± 31.17	232.36 ± 15.76	165.51 ± 2.54
<i>Lxr β</i>	6.48 ± 2.35	6.37 ± 1.22	7.26 ± 1.58	7.26 ± 0.15	7.50 ± 1.01	12.06 ± 1.29	9.53 ± 0.32
<i>Rxr α</i>	631.83 ± 40.54	321.42 ± 18.66^{**}	414.05 ± 10.14	432.84 ± 19.63	525.97 ± 16.29	497.06 ± 36.49	612.73 ± 33.02
<i>Rxr β</i>	50.97 ± 7.01	39.87 ± 3.08	39.28 ± 1.73	50.38 ± 6.31	85.94 ± 0.50	57.64 ± 12.24	63.78 ± 3.84
<i>Rxr γ</i>	2.21 ± 2.31	1.57 ± 1.18	1.62 ± 0.99	1.59 ± 0.46	3.47 ± 3.6	4.57 ± 1.91	3.28 ± 0.30
<i>Ror α</i>	684.70 ± 77.43	386.92 ± 62.60	660.44 ± 59.14	457.74 ± 39.44	927.52 ± 109.80	1900.72 ± 242.43^{***}	852.56 ± 101.46
<i>Ror γ</i>	11.81 ± 2.25	8.70 ± 0.44	12.44 ± 4.38	6.62 ± 1.06	7.80 ± 2.09	3.54 ± 0.53[*]	24.41 ± 6.19
<i>Hnf4 α</i>	2.19 ± 0.66	1.84 ± 0.73	2.36 ± 0.39	1.61 ± 0.29	1.45 ± 0.32	1.41 ± 0.24	2.15 ± 0.58
<i>Hnf4 γ</i>	33.79 ± 6.41	23.00 ± 1.40	37.19 ± 7.05	46.10 ± 3.02	27.27 ± 2.56	16.15 ± 2.14	34.48 ± 4.68
<i>Ear 2</i>	219.86 ± 42.03	186.17 ± 5.74	251.13 ± 16.12	250.40 ± 2.59	205.03 ± 7.82	77.06 ± 1.57	225.35 ± 15.61
<i>Shp</i>	0.16 ± 0.06	0.11 ± 0.01	0.23 ± 0.09	0.20 ± 0.12	0.06 ± 0.02	0.28 ± 0.03	0.29 ± 0.05

Table 1: Quantitative real-time PCR of ONRs in C2C12 cells treated with 10 nM insulin over 48 h.

using chemiluminescence SuperSignal West Pico Substrate (Pierce®) and visualised using UVITEC Alliance digital imaging system (Thermo Fisher Scientific®).

Statistics

Statistical analyses were performed using Microsoft Excel software and all data were analyzed using a Student's unpaired t-test \pm SD, where $*p \leq 0.05$, $**p \leq 0.01$, and $***p \leq 0.001$.

Results

The effects of insulin on the phosphorylation of AKT and the production of insulin resistance model in C2C12 skeletal muscle cells

In order to create an insulin-resistant skeletal muscle cell line, we stimulated C2C12 cells with 10 nM of insulin over 0, 0.5, 2, 4, 8, 24, and 48 h replacing the media and insulin every 8 h. This method has been successfully used in a number of studies to create insulin-resistant C2C12 cells [11,12]. Total cellular protein was extracted using RIPA buffer and 20 μ g of total cellular protein was subjected to SDS-PAGE, and subsequently blotted onto Immobilon-PVDF membrane. The relative levels of pAKT was detected relative to total AKT (Figure 1). Following 30 min of insulin treatment there was an increase in the levels of pAKT that were further increased at 2 and 4 h of insulin treatment. The level of phosphorylation then rapidly decreased at 8 h and became almost undetectable at 24 and 48 h (Figure 1). Overall, there was no change in total AKT protein observed, suggesting that the C2C12 cells had obtained the insulin-resistant phenotype.

The effects of insulin on the mRNA expression of orphan nuclear receptors in an insulin-resistant C2C12 skeletal muscle cell line

To determine if any of the ONRs responded to increases in insulin-resistance, we analysed a progressively insulin-resistant C2C12 skeletal muscle cell line. We analysed several ONRs by quantitative real-time PCR and observed several significant changes in a number of the ONRs as the cells became increasingly insulin resistant (Table 1). Of these, *Coup-tf1* and *Coup-tf2*, *Ror γ* and *Rar γ* were significantly decreased at 24 h of insulin treatment while *Ppar β* , *Ppar γ* , *Nor-1*, *Nurr1*, *Nur77*, *Reverb α* , *Rar α* , *Rar β* , *Err α* , *Ror α* and *Mr* were all significantly increased at 24 h of insulin treatment (Table 1). Other significant changes were observed for *Nor-1* (increased at 2 h), *Nur77* (increased at 0.5 and 2 h), *Reverb α* (increased at 8 h), *Rxr α* (decreased at 0.5 h), and *Vdr* (increased at 8 h) (Table 1). A representative figure (Figure 2) shows in graphical form a number of the orphan nuclear receptors that

were significantly changes in the presence of 10 nM insulin and the acquisition of the insulin-resistant skeletal muscle phenotype.

Discussion


This study identified the regulatory response of several ONRs in response to skeletal muscle cells becoming increasingly resistant to insulin over time. We identified that 10 nM of insulin was sufficient to induce the phosphorylation of AKT after 30 min of treatment and that this phosphorylation was transient and rapidly declined post 2 h. This is supported by several studies that demonstrated that insulin resistant could be measured by the amount of pAKT relative to total AKT protein over time with chronic insulin treatment [12-15]. Thus, reduced pAKT levels are consistent with an increase in insulin resistance. Given that the ONR regulate genes are involved in many cellular mechanism, including metabolism, and have been linked to metabolic conditions including type 2 diabetes [16], it is reasonable to conclude that they may also be implicated in insulin resistance.


A number of ONRs were significantly regulated on the acquisition of the insulin resistant phenotype in C2C12 skeletal muscle cells including *Coup-tf1*, *Coup-tf2*, *Ppar β* , *Nor-1*, *Nurr1*, *Nur77*, *Reverb α* , and *Rora* (Table 1). These ONRs have various roles in the context of metabolism and specifically in relation to carbohydrate and lipid metabolism and energy expenditure [1], and are discussed below.

Coup-tf1 and *Coup-tf2* were both significantly down-regulated at 24 h of insulin treatment in the insulin-resistant skeletal muscle cell line. This is consistent with previous studies that identified that exogenous insulin reduced the levels of *Coup-tf2* mRNA and protein in INS-1 β -cell lines and pancreatic islet β -cells [17]. Moreover, these authors found that C57BL/6J mouse hepatocytes that were cultured with 10 nM of insulin over 24 h had reduced levels of *Coup-tf2*. However, it is difficult to determine whether these effects in both our studies and the studies by Perilhou et al. [17] were due to insulin directly or indirectly targeting *Coup-tf2* expression or due to the cells (skeletal muscle and hepatocytes) undergoing changes in insulin resistance. From this study and others [12,18], chronic insulin treatment of 10 nM over 24 h is enough to reduce levels of pAkt and is indicative of the cells acquiring an insulin-resistant phenotype. *Coup-tf2* overexpression in C2C12 skeletal muscle cells also increased *Pgc1 α* and *Glut4* mRNA and protein and suggest that these cells may have improved insulin sensitivity and glucose uptake [19]. In fact, in mice that had a pancreatic β -cell specific *Coup-tf2* deficiency these animals had altered insulin secretion that was associated with peripheral insulin resistance and impaired glucose sensitivity [20].

Ppar β was significantly up-regulated at 24 h of insulin treatment in contrast to the other family members *Ppar α* and *Ppar γ* who showed no response to the acquisition of the insulin resistant phenotype. *Ppar β* plays an important role in controlling fatty acid metabolism in skeletal muscle cells [21]. Previous studies have shown that *Ppar β* enhances insulin sensitivity [22] and prevents lipid-induced endoplasmic reticulum stress, and thus insulin resistance, in mouse and human skeletal muscle [23]. Accordingly, the increase in *Ppar β* in the progressively insulin-resistant skeletal muscle cells may be a compensatory action to regulate insulin sensitivity. Actually, *Ppar β* activation prevented palmitate-induced inflammation and insulin resistance in skeletal muscle cells by increasing fatty acid oxidation [23].

The NR4A family of ONRs (*Nor-1*, *Nurr1* and *Nur77*) were all induced at various times as the skeletal muscle cells became progressively





insulin resistant. There is little information available on the role of the NR4As in insulin resistance however, studies by Fu et al. [24] found that *Nur77* and *Nor-1* were induced with 10 nM insulin in 3T3-L1 adipocytes cells at 1 h and 2 h, respectively. This is in collaboration to our studies where we show both *Nur77* and *Nor-1* induced by 10 nM insulin at 30 min and 2 h (*Nur77*) and 2 h (*Nor-1*). We also observed significant induction of *Nurr1* during this 2 h time period, however in addition, we found that all three NR4As were significantly reduced to basal levels over 4 and 8 h, before being up-regulated at 24 h of insulin treatment. The increase at 24 h for all three NR4As is suggestive of the acquisition of the insulin-resistant phenotype due to the fact that the NR4As respond within 2 h of insulin treatment before falling to basal levels [25]. As C2C12 cells become insulin resistant, they undergo oxidative stress and impaired gene expression of the insulin signaling pathway [26]. It has been revealed that the NR4As are also induced under a host of functions including changes in metabolism, insulin sensitivity, and oxidative stress conditions [27].

Reverba was significantly induced at 8 and 24 h of insulin treatment and the acquisition of the insulin-resistant phenotype. This ONR plays a crucial role in the regulation of circadian rhythms and including those associated with food intake [28]. Mice that lack *Reverba* display changes in their daily energy homeostasis and predisposition to diet-induced obesity [29]. Moreover, the ablation of *Reverba* by siRNA in islet cells and MIN-6 pancreatic cells impaired glucose-induced insulin secretion, decreased genes implicated in lipid metabolism, and impaired β -cell function [30]. It was suggested by these authors that *Reverba* may therefore play a critical role in the daily dynamics of insulin secretion. Equally, *Erra* was significantly upregulated at 24 h following insulin treatment. Similar to *Reverba* there is little information on the role of this ONR in insulin resistance. The ERRs (α and β) are involved in transcriptional control of cellular energy metabolism and may also be implicated in the aetiology of metabolic disorders, such as type 2 diabetes and metabolic syndrome [31].

These studies show that some of the ONRs are sensitive to changes

in the skeletal muscle phenotype resulting from insulin-induced, skeletal muscle insulin-resistance and therefore may be amendable to therapeutic intervention to treat or better manage insulin resistance and disease progression. Further studies are required to delineate the role of these ONRs in insulin resistance progression and to establish a platform for drug therapy in skeletal muscle-associated insulin resistance and subsequent disease states.

References

- Myers SA, Wang SC, Muscat GE (2006) The Chicken Ovalbumin Upstream Promoter-Transcription Factors Modulate Genes and Pathways Involved in Skeletal Muscle Cell Metabolism. J Biol Chem 281: 24149-24160.
- Evans RM, Mangelsdorf DJ (2014) Nuclear Receptors, RXR, and the Big Bang. Cell 157: 255-266.
- Baranowski M, Zabielski P, Blachnio-Zabielska AU, Harasim E, Chabowski A, et al. (2014) Insulin-sensitizing effect of LXR agonist T0901317 in high-fat fed rats is associated with restored muscle GLUT4 expression and insulin-stimulated AS160 phosphorylation. Cell Physiol Biochem 33: 1047-1057.
- Vacca M, Degirolamo C, Mariani-Costantini R, Palasciano G, Moschetta A (2011) Lipid-sensing nuclear receptors in the pathophysiology and treatment of the metabolic syndrome. Wiley Interdiscip Rev Syst Biol Med 3: 562-587.
- Beaven SW, Matveyenko A, Wroblewski K, Chao L, Wilpitz D, et al. (2013) Reciprocal regulation of hepatic and adipose lipogenesis by liver X receptors in obesity and insulin resistance. Cell Metab 18: 106-117.
- Shi Y (2007) Orphan nuclear receptors in drug discovery. See comment in PubMed Commons below Drug Discov Today 12: 440-445.
- Bonet ML, Ribot J, Palou A (2012) Lipid metabolism in mammalian tissues and its control by retinoic acid. Biochim Biophys Acta 1821: 177-189.
- Kim YD, Kim YH, Cho YM, Kim DK, Ahn SW, et al. (2012) Metformin ameliorates IL-6-induced hepatic insulin resistance via induction of orphan nuclear receptor small heterodimer partner (SHP) in mouse models. Diabetologia 55: 1482-1494.
- Wang SC, Muscat GE (2013) Nuclear receptors and epigenetic signaling: novel regulators of glycogen metabolism in skeletal muscle. IUBMB Life 65: 657-664.
- Yang M, Wei D, Mo C, Zhang J, Wang X, et al. (2013) Saturated fatty acid palmitate-induced insulin resistance is accompanied with myotube loss and

- the impaired expression of health benefit myokine genes in C2C12 myotubes. *Lipids Health Dis* 12: 104.
11. Chavez JA, Summers SA (2003) Characterizing the effects of saturated fatty acids on insulin signaling and ceramide and diacylglycerol accumulation in 3T3-L1 adipocytes and C2C12 myotubes. *Arch Biochem Biophys* 419: 101-109.
 12. Kumar N, Dey CS (2003) Development of insulin resistance and reversal by thiazolidinediones in C2C12 skeletal muscle cells. *Biochem Pharmacol* 65: 249-257.
 13. Cantley LC (2002) The phosphoinositide 3-kinase pathway. *Science* 296: 1655-1657.
 14. Houstis N, Rosen ED, Lander ES (2006) Reactive oxygen species have a causal role in multiple forms of insulin resistance. *Nature* 440: 944-948.
 15. Myers SA, Nield A, Chew GS, Myers MA (2013) The zinc transporter, Slc39a7 (Zip7) is implicated in glycaemic control in skeletal muscle cells. *PLoS One* 8: e79316.
 16. Tontonoz P, Hu E, Spiegelman BM (1994) Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. *Cell* 79: 1147-1156.
 17. Perilhou A, Tourrel-Cuzin C, Kharroubi I, Henique C, Fauveau V, et al. (2008) The transcription factor COUP-TFII is negatively regulated by insulin and glucose via Foxo1- and ChREBP-controlled pathways. *Mol Cell Biol* 28: 6568-6579.
 18. Berdichevsky A, Guarente L, Bose A (2010) Acute oxidative stress can reverse insulin resistance by inactivation of cytoplasmic JNK. *J Biol Chem* 285: 21581-21589.
 19. Crowther LM, Wang SC, Eriksson NA, Myers SA, Murray LA, et al. (2011) Chicken ovalbumin upstream promoter-transcription factor II regulates nuclear receptor, myogenic, and metabolic gene expression in skeletal muscle cells. *Physiol Genomics* 43: 213-227.
 20. Bardoux P, Zhang P, Flamez D, Perilhou A, Lavin TA, et al. (2005) Essential role of chicken ovalbumin upstream promoter-transcription factor II in insulin secretion and insulin sensitivity revealed by conditional gene knockout. *Diabetes* 54: 1357-1363.
 21. Coll T, Rodríguez-Calvo R, Barroso E, Serrano L, Eyre E, et al. (2009) Peroxisome proliferator-activated receptor (PPAR) beta/delta: a new potential therapeutic target for the treatment of metabolic syndrome. *Curr Mol Pharmacol* 2: 46-55.
 22. Wang YX, Lee CH, Tiep S, Yu RT, Ham J, et al. (2003) Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. *Cell* 113: 159-170.
 23. Salvadó L, Barroso E, Gómez-Foix AM, Palomer X, Michalik L, et al. (2014) PPARbeta/delta prevents endoplasmic reticulum stress-associated inflammation and insulin resistance in skeletal muscle cells through an AMPK-dependent mechanism. *Diabetologia* 57: 2126-2135.
 24. Fu Y, Luo L, Luo N, Zhu X, Garvey WT (2007) NR4A orphan nuclear receptors modulate insulin action and the glucose transport system: potential role in insulin resistance. See comment in PubMed Commons below *J Biol Chem* 282: 31525-31533.
 25. Gao M, Bu L, Ma Y, Liu D (2013) Concurrent activation of liver X receptor and peroxisome proliferator-activated receptor alpha exacerbates hepatic steatosis in high fat diet-induced obese mice. *PLoS One* 8: e65641.
 26. Yu R, Luo J, Yu R (2015) Docosahexaenoic acid attenuated palmitate-induced insulin resistance in C2C12 cells. *Zhonghua Yi Xue Za Zhi* 95: 226-230.
 27. Ranhosira HS (2015) The NR4A orphan nuclear receptors: mediators in metabolism and diseases. *J Recept Signal Transduct Res* 35: 184-188.
 28. Duez H, Staels B (2009) Rev-erb-alpha: an integrator of circadian rhythms and metabolism. *J Appl Physiol* (1985) 107: 1972-1980.
 29. Delezie J, Dumont S, Dardente H, Oudart H, Gréchez-Cassiau A, et al. (2012) The nuclear receptor REV-ERB α is required for the daily balance of carbohydrate and lipid metabolism. *FASEB J* 26: 3321-3335.
 30. Vieira E, Marroquí L, Batista TM, Caballero-Garrido E, Carneiro EM, et al. (2012) The clock gene Rev-erb α regulates pancreatic β -cell function: modulation by leptin and high-fat diet. *Endocrinology* 153: 592-601.
 31. Audet-Walsh É, Giguère V (2015) The multiple universes of estrogen-related receptor α and γ in metabolic control and related diseases. *Acta Pharmacol Sin* 36: 51-61.